TICKERNERD
Menu
ABTABTHealthcare · Medical Devices

ABT Stock Forecast: Abbott Laboratories Price Predictions for 2026-2027

Last close, 24 Sept 2026
$101
−2.34% on the day

The 27 Wall Street analysts covering Abbott Laboratories hold a median 12-month price target of $120 — +18.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 23 Sept 2026 — in the upper half.

Market cap
$179.1B
Ticker Nerd rank
57 / 100
Median analyst target
$120
Analysts covering
27
Revenue$11.2B+7.8% y/y
Operating income$1.3B
Net income$1.1B
Free cash flow$916.0M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.1%
1M
−13.4%
YTD
−17.8%
1Y
−22.8%
From 52W high
−23.2%
From 52W low
+23.3%
$82
$132
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Abbott Laboratories on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Quality
83
Value
81
Revisions
78
Growth
49
Accruals
39
Issuance
37
Momentum
35
Size
1

Volatility (100): The share price has been relatively steady.

Momentum (35): The shares have been drifting down relative to others.

Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$90$100$110$120$130$140Oct 25Jan 26Apr 26Jul 26ABTHigh $135Median $120Low $103

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says27 analysts
22 Buy5 Hold0 Sell
Low $103Median $120High $135

The green dot is the last close — the median target sits +18.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
8 Sept 2026TD CowenReiteratesBuy$135
25 Aug 2026TD CowenMaintainsBuy—
21 Aug 2026TD CowenMaintainsBuy$115 → $135
21 Aug 2026TD CowenMaintainsBuy—
14 Aug 2026CitigroupMaintainsBuy—
13 Aug 2026Wolfe ResearchUpgradeOutperform—
13 Aug 2026Wolfe ResearchUpgradeOutperform$130
28 July 2026UBSMaintainsBuy$135 → $125
28 July 2026UBSMaintainsBuy—
17 July 2026BTIGMaintainsBuy—
17 July 2026BTIGMaintainsBuy$131 → $134
17 July 2026CitigroupMaintainsBuy$108 → $112
17 July 2026CitigroupMaintainsBuy—
17 July 2026Evercore ISI GroupMaintainsOutperform$112 → $120
17 July 2026Evercore ISI GroupMaintainsOutperform—
17 July 2026JP MorganMaintainsOverweight$110 → $120
17 July 2026JP MorganMaintainsOverweight—
17 July 2026Piper SandlerReiteratesOverweight$115 → $118
17 July 2026Piper SandlerReiteratesOverweight—
17 July 2026RBC CapitalReiteratesOutperform$130

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ABT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Abbott Laboratories returned −22.8% against +17.4% for the S&P 500, dividends included.

ABT vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26ABTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.7%
Analysts raising
5
Analysts cutting
1
Fundamentals

Abbott Laboratories (ABT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
33.5×

Cheaper than 23% of US stocks

Price / sales
3.8×

Cheaper than 32% of US stocks

Price / book
3.5×

Cheaper than 29% of US stocks

EV / EBITDA
17.7×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
13.0%

Higher than 59% of US stocks

Earnings growth (YoY)
−47.8%

Higher than 11% of US stocks

Gross margin
56.2%

Higher than 69% of US stocks

Operating margin
14.7%

Higher than 72% of US stocks

Net margin
11.6%

Higher than 73% of US stocks

Returns & dividend
Return on equity
10.6%

Higher than 65% of US stocks

Return on assets
5.3%

Higher than 78% of US stocks

Dividend yield
2.4%

Higher than 52% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Abbott Laboratories (ABT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Abbott Laboratories has a market value of $179.1B and an enterprise value of $206.8B.

  • Revenue in the twelve months to 31 Mar 2026: $45.1B. The latest quarter grew 13.0% year on year.

  • Net income over the same four quarters: $6.3B, a 13.9% net margin.

  • Diluted earnings per share, trailing twelve months: $3.57.

  • Free cash flow in the twelve months to 31 Mar 2026: $7.4B, after $2.1B of capital spending.

  • Abbott Laboratories spent $793.0M on share buybacks and $4.2B on dividends in the twelve months to 31 Mar 2026.

  • Shares outstanding: 1.7B.

  • Trailing P/E: 33.5×; forward P/E: 17.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.43%, paying out 79% of earnings.

  • Abbott Laboratories employs 122,000 people — $370K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

ABT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ABTAbbott Laboratories$179.1B
57
MDTMedtronic PLC$114.5B
87
SYKStryker Corp.$104.6B
73
BSXBoston Scientific Corp.$66.1B
56
EWEdwards Lifesciences Corp.$50.0B
90
DXCMDexCom, Inc.$33.9B
99
GEHCGE Healthcare Technologies, Inc.$30.1B
63

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Abbott Laboratories — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABT news & analysis

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research · 23 Sept 2026neutral

Abbott Laboratories (ABT) has recently been one of the most-watched stocks on Zacks.com. The article notes that investors are exploring what may lie ahead for the stock, given its heightened visibility.

Why it matters — The increased attention from Zacks users signals elevated investor interest in ABT, making it relevant for watchers tracking market sentiment and near-term focus on the company.

Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health

PRNewsWire · 23 Sept 2026positive

Abbott announced a partnership with Berry Street to combine its Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, aiming to help consumers translate glucose insights into healthier behaviors for better metabolic health.

Why it matters — This expands Abbott's digital health and personalized nutrition offerings in the metabolic health space, potentially broadening the reach and applications of its Lingo CGM device.

Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth

The Motley Fool · 21 Sept 2026neutral

The article compares Abbott Laboratories with Intuitive Surgical, examining their recent quarterly revenue trends to illustrate a classic investing principle. It notes that Abbott generates revenue through a diverse portfolio of medical devices, diagnostic test systems, nutritional formulas, and generic pharmaceutical products.

Why it matters — ABT watchers would care because the revenue comparison highlights how Abbott's diversified business model positions it relative to a focused competitor.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks Investment Research · 21 Sept 2026neutral

The article suggests investors use the Zacks Earnings ESP tool to identify medical stocks likely to beat quarterly earnings estimates. The headline highlights two medical stocks, though the excerpt does not name Abbott Laboratories explicitly.

Why it matters — The article points to tools and strategies for spotting medical-sector stocks poised to top earnings estimates, which could be relevant to those tracking Abbott Laboratories' earnings performance.

3 Dividend Stocks to Buy and Hold for 10 Years

The Motley Fool · 18 Sept 2026positive

In a Motley Fool article listing three dividend stocks to buy and hold for ten years, Abbott Laboratories is highlighted, with the journalist noting that its core medical device business remains strong and that the company has attractive opportunities elsewhere. Pfizer is also mentioned for its deep pipeline.

Why it matters — The article signals favourable long-term investor attention on Abbott, emphasising the strength of its medical devices segment and growth potential in other areas, which is relevant for those tracking the company's outlook.

FAQ

Frequently asked questions about ABT stock

What is the ABT stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Abbott Laboratories have a median 12-month price target of $120, with estimates ranging from $103 to $135. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABT stock a buy right now?

Of the 27 analysts covering Abbott Laboratories, 22 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abbott Laboratories 57 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABT?

As at 23 Sept 2026, Abbott Laboratories ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will ABT stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +18.7% from the last close, and Ticker Nerd's factor model ranks Abbott Laboratories 57 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABT stock forecast for 2030?

No analyst covering Abbott Laboratories publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $135 over the next 12 months.

How has ABT stock performed over the past year?

Abbott Laboratories returned -22.8% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Abbott Laboratories do?

Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical devices, diagnostic systems, nutritional products, and branded generic medicines. Its portfolio spans cardiovascular care, diabetes management, electrophysiology, structural heart, neuromodulation, laboratory diagnostics, point-of-care testing, adult and pediatric nutrition, and established pharmaceuticals for international markets.

What is the latest news on ABT?

The most recent item we track (Zacks Investment Research, 23 Sept 2026): "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It". Abbott Laboratories (ABT) has recently been one of the most-watched stocks on Zacks.com. The article notes that investors are exploring what may lie ahead for the stock, given its heightened visibility.

Company

About Abbott Laboratories.

Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical devices, diagnostic systems, nutritional products, and branded generic medicines. Its portfolio spans cardiovascular care, diabetes management, electrophysiology, structural heart, neuromodulation, laboratory diagnostics, point-of-care testing, adult and pediatric nutrition, and established pharmaceuticals for international markets. Abbott serves hospitals, laboratories, healthcare providers, pharmacies, and consumers through products used in chronic disease management, clinical testing, and everyday nutrition. The company plays a significant role in the healthcare market by combining device technology, diagnostics, and nutrition into a diversified platform that supports patient care across multiple settings. Abbott Laboratories is headquartered in Abbott Park, Illinois, and operates with a global commercial footprint across numerous countries.

CEO Mr. Robert B. Ford · 122,000 employees · United States · https://www.abbott.com